Table of Contents
Xenon Pharmaceuticals reported positive topline Phase 3 X-TOLE2 results on March 9, 2026, saying azetukalner met the main goal in focal onset seizures. In the trial, the 25 mg dose produced a 53.2% median reduction in monthly seizure frequency over 12 weeks, versus 10.4% for placebo. Reuters also reported a 42.7% placebo-adjusted reduction for the 25 mg dose. More than half of patients receiving 25 mg achieved at least a 50% reduction in seizure frequency, compared with 20.8% on placebo.
The market response was immediate. Reuters reported that Xenon shares rose 45% in morning trading and reached an all-time high of $62.64 following the announcement. The same report said at least two analysts see azetukalner as a more than $2 billion peak-sales opportunity. Reuters also cited analyst commentary that the result exceeded the range some investors had been debating ahead of the readout.
On a call with analysts, Chief Commercial Officer Darren Cline said the company believes the data and the drug’s novel mechanism support optimized pricing. Reuters reported that Xenon plans flat pricing across four labeled doses, 10 mg, 15 mg, 20 mg, and 25 mg, so physicians can start patients at any dose level and escalate treatment without dose-based cost differences.
According to Reuters, Xenon expects to file for approval in the third quarter of 2026, with an FDA decision likely in late 2027 or early 2028.
This version is source-safe against the Reuters text provided by the user. Claims about Phase 2b comparisons, baseline patient burden, safety details, dosing convenience, drug-drug interactions, regulatory exclusivity within the KV7 class, and the April 19 American Academy of Neurology presentation are omitted because they were not verifiable from the accessible source set.
Source: Reuters, Xenon Pharmaceuticals Inc.
Comments